Gastrodin Prevents Cognitive Decline Related to Cardiopulmonary Bypass
1 other identifier
interventional
200
1 country
1
Brief Summary
The incidence of cognitive decline related to CPB ranges from 20% to 80%, which may affect length of hospital stay, quality of life, the rehabilitation process, and work performance.However, there is no method to prevent the decline.Gastrodin,the active constituent of gastrodia elata, has been widely used for the treatment of paralysis, hemiplegia, headache, vertigo, and Alzheimer's disease. Gastrodin is safe. No severe side-effect has been observed in the treatment. We postulate that gastrodin would attenuate the causative parameters of cognitive dysfunction related to CPB and would be an effective drug to prevent the decline as a result.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_4
Started Feb 2006
Shorter than P25 for phase_4
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2006
CompletedFirst Submitted
Initial submission to the registry
February 27, 2006
CompletedFirst Posted
Study publicly available on registry
February 28, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2006
CompletedFebruary 28, 2006
January 1, 2006
February 27, 2006
February 27, 2006
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Gastrodin markedly prevents cognitive decline related to cardiopulmonary bypass
Secondary Outcomes (1)
neuropsychological tests
Interventions
Eligibility Criteria
You may qualify if:
- Adult patients undergo mitral valve replacement surgery.
You may not qualify if:
- Thrombi in left atrium, a history of symptomatic cerebrovascular disease, diabetes, psychiatric illness, renal disease, or active liver disease, less than a seven-grade education, or who cannot read.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Anesthesiology, Union Hospital
Wuhan, Hubei, 430022, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Shihai Zhang
Department of Anesthesiology, Union Hosiptal, Tongji Medical College, Huazhong University of Science and Technology
- PRINCIPAL INVESTIGATOR
Shihai Zhang, M.D., Ph.D.
Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
February 27, 2006
First Posted
February 28, 2006
Study Start
February 1, 2006
Study Completion
May 1, 2006
Last Updated
February 28, 2006
Record last verified: 2006-01